Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts. 

Market Access Insights

Merck KGaA’s $1.3 Billion Silence Therapeutics Buyout: What Does It Mean for Market Access?

Summary

Merck KGaA announced on October 19, 2026 that it will acquire Silence Therapeutics for about $1.3 billion in cash, paying $20 per U.S.-listed share. The offer carries a 130% premium over Silence’s prior trading price, and shareholders holding 14% of the voting power have already agreed to it. The deal gives Merck KGaA control of divesiran, a small interfering RNA (siRNA) therapy for polycythemia vera, a rare blood disorder in which the bone marrow overproduces red blood cells. However, the transaction rests on Phase 2 data only, and the companies expect it to close in the first quarter of 2027.

Access Impact

This is a premium built on early data. Divesiran has not yet entered Phase 3 testing, the stage that regulators and payers rely on most heavily when deciding access and price. Consequently, the deal highlights a recurring tension in market access: strong early results do not guarantee durable clinical effectiveness or value once a drug reaches a formal access decision. For polycythemia vera, this falls mainly under two of the domains MARA systematically scores for every rated asset: Evidence Quality and Comparator Selection. Both will shape how divesiran is treated once real evidence, not analyst sentiment, is on the table.

Evidence Quality

Divesiran’s case currently rests on Phase 2 results alone. These are the data Merck KGaA used to justify the price, and some analysts called the asset potentially “best in class.” However, Phase 2 studies are smaller and shorter than Phase 3 trials, and they often overstate benefit relative to later, larger studies. Specifically, the gap between Phase 2 promise and Phase 3 confirmation is where many assets lose value on reassessment by health technology assessment bodies. Until Phase 3 data exists, any claim about divesiran’s real clinical effectiveness remains provisional, however encouraging the early signal looks today.

Comparator Selection

Divesiran will not enter an empty field. Takeda and Protagonist’s Mimrylo and Incyte’s Jakafi are already approved and in use for polycythemia vera. As a result, payers and HTA bodies will not judge divesiran in isolation; they will measure it against these established treatments. A new therapy that cannot show a clear advantage over the current standard of care typically receives a weaker access outcome, even after full regulatory approval. The relevant comparator for any future submission is whichever product is actually prescribed in practice, not necessarily the one a company prefers to cite in its own materials. Notably, both Mimrylo and Jakafi already have real-world use and payer familiarity, which gives them an advantage that no amount of early trial enthusiasm can fully offset.

Clinical Effectiveness

The underlying science for divesiran may well be sound. Still, “potentially best in class,” as some analysts described it, is not the same as a demonstrated, statistically confirmed advantage shown in a Phase 3 trial. Moreover, the acquisition is expected to close well before any Phase 3 readout is available. Therefore, the commercial logic behind this deal currently rests more on the size of the addressable market and the strength of an early signal than on confirmed, head-to-head clinical superiority over Mimrylo or Jakafi. Even so, polycythemia vera remains a condition with real unmet need, and a genuinely durable Phase 3 result could still change the competitive picture in divesiran’s favor.

Risk Signal

A $1.3 billion bet on a trial that has not yet happened. For an investor or portfolio manager, the Merck KGaA-Silence deal is a reminder that acquisition price and market access risk can move in opposite directions. A high premium reflects confidence in the science; it does not confirm that payers will reimburse the product at a price that supports the deal’s economics. Specifically, if Phase 3 data for divesiran disappoints, or if Mimrylo or Jakafi strengthen their position in the meantime, the access case for divesiran could narrow considerably. What independent, defensible benchmark would an investment committee rely on to assess that risk before the next funding round or deal is signed?

#MarketAccess #HTA #MARArating #PolycythemiaVera #siRNA

Explore MARA’s independent drug ratings: https://mararating.com/mara-ratings-list

Related articles